References
Benson, A. B., Myerson, R. J., & Hoffman, J. (2007). Pancreatic, neuroendocrine GI, and adrenal cancers. In R. Pazdur, L. R. Coia, W. J. Hoskins, & L. D. Wagnman (Eds.), Cancer management: A multidisciplinary approach (10th ed., pp. 287-310). Lawrence, KS: CMP Medica.
Kulke, M. H., Lenz, H., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J…. Fuchs, C. S. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 26, 3403-3410. dx.doi.org/10.1200/JCO.2007.15.9020
Parra, I., Remacha, A., Costilla, S., & Caleron, J. A. (2002). Thymic carcinoid tumors. Canadian Respiratory Journal, 9, 215-216.
Pinchot, S. N., Holen, K., Sippel, R. S., & Chen, H. (2008). Carcinoid tumors. Oncologist, 13, 1255-1269. dx.doi.org/10.1634/theoncologist.2008-0207
Rinke, A., Muller, H., Schade-Brittinger, C., Klose, K., Barth, P., Wied, M…. Arnold, R. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Journal of Clinical Oncology, 27, 4656-4663. dx.doi.org/10.1200/JCO.2009.22.8510
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S…. Meric-Bernstam, F. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to- intermediate-grade neuroendocrine tumors: Results of a phase II study. Journal of Clinical Oncology, 26, 4311-4318.
Yao, J.C, Phan, A. T., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S. J…. Ajani, J. A. (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide. Journal of Clinical Oncology, 26, 1316-1323. dx.doi.org/10.1200/JCO.2007.13.6374
Zuetenhorst, J. M., & Taal, B. G. (2005). Metastatic carcinoid tumors: A clinical review. Oncologist, 10, 123-131.